# Continues Cicatricial Perfusion of Ropivacaine Versus Placebo After Mastectomy : Rehabilitation After Treatment

> **NCT02525211** · PHASE3 · TERMINATED · sponsor: **Institut Paoli-Calmettes** · enrollment: 59 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Ropivacaine
- **DRUG:** physiological saline

## Key facts

- **NCT ID:** NCT02525211
- **Lead sponsor:** Institut Paoli-Calmettes
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2012-10
- **Primary completion:** 2017-04-21
- **Final completion:** 2017-10
- **Target enrollment:** 59 (ACTUAL)
- **Why stopped:** Recruitment defect
- **Last updated:** 2026-04-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02525211

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02525211, "Continues Cicatricial Perfusion of Ropivacaine Versus Placebo After Mastectomy : Rehabilitation After Treatment". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02525211. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*